A maker of computer software that lets pharmaceutical companies test drugs "on screen" before they ever reach a lab or a patient. Its tools—like GastroPlus, ADMET Predictor, and DILIsym—predict how a compound moves through the body and whether it might harm the liver, and its services help with modeling and clinical trial training. Founder Walt Woltosz started the company in 1996 after bringing aerospace-style simulation ideas into drug development. Its name simply joins "simulations" with a "plus," a nod to the extra technology baked in.
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: -584.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.